search
Back to results

EDS in Ataxia Telangiectasia Patients (ATTeST)

Primary Purpose

Nervous System Disease, Genetic Syndrome

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
EDS-EP dose range of ~5-10 mg DSP/infusion
EDS-EP dose range of ~14-22 mg DSP/infusion
Placebo
Sponsored by
Erydel
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Nervous System Disease focused on measuring Ataxia Teleangiectasia, AT, EryDex system, Dexamethasone, Dexamethasone sodium phosphate

Eligibility Criteria

6 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Main Inclusion Criteria:

  • Patient meets clinical criteria for diagnosis of AT. The neurological signs of AT (incoordination of the head and eyes in lateral gaze deflection, gait ataxia associated with an inappropriately narrow base) must be documented.
  • Patient is in autonomous gait or is helped by periodic use of a support.
  • Patient will be investigated for the proven genetic diagnosis of AT (prior documentation or by central laboratory test report).
  • Patient is at least 6 years of age, of either sex
  • Body weight > 15 kg.
  • The patient and his/her parent/caregiver (if below the age of consent), or a legal representative, has provided written informed consent to participate. If consent is provided solely by the caregiver in accordance with local regulations, the patient must provide assent to participate in the study.

Main Exclusion Criteria:

General

  • Females that are

    1. pregnant, or are breast-feeding (for EU countries only);
    2. of childbearing potential, pregnant, or are breast-feeding (for US and Rest of World countries).

      Females of childbearing potential using adequate birth control, as determined by their Health Care Provider, will be eligible.

  • A disability that may prevent the patient from completing all study requirements.
  • Current participation in another clinical study. Medical History and Current Status
  • CD4+ lymphocytes count <400/mm3 (for patients 6 years of age) or <150/mm3 (for patients >6 years). In presence of oral infections, like oral candidiasis, documented at the screening or recurrent as per medical history documentation, the limit increases to <200/mm3 (for patients > 6 years).
  • Loss/removal of 250 mL or more of blood within the past 4 weeks prior to screening.
  • Current neoplastic disease or previous neoplastic disease not in remission for at least 2 years.
  • History of severe impairment of the immunological system.
  • Severe or unstable pulmonary disease.
  • Uncontrolled diabetes. Patients with diabetes that has been stabilized (i.e. no hypoglycemic or hyperglycemic episodes in the past 3 months) will be eligible.
  • Any other severe, unstable, or serious disease or condition that in the Investigator's opinion would put the patient at risk for imminent life-threatening morbidity, need for hospitalization, or mortality.
  • Any clinically significant abnormality on standard laboratory examinations (hematology, biochemistry, urinalysis) at screening that remains abnormal on repeat testing. Eligibility of patients with abnormal laboratory test values will be determined by the Investigator in consultation with the Medical Monitor.
  • Confirmed hemoglobinopathies, e.g. hemoglobin C disease, sickle cell anemia, or thalassemia.
  • Moderate or severe renal and/or hepatic impairment. Prior/Concomitant Medication
  • Any previous oral or parenteral steroid use within 4 weeks before Baseline. Treatment with inhaled or intranasal steroids for asthma or allergies, as well as use of topical steroids will be permitted
  • Chronic condition or prior allergic reaction representing a contraindication to the use of dexamethasone or other steroid drugs.
  • Has participated in any other trial with an investigational drug and received a dose within 30 days or 10 half-lives (whichever is greater) from the start of the 30-day Screening Period.
  • Has participated in a previous trial with EDS.
  • Requires any concomitant medication prohibited by the protocol.
  • Has taken a drug or treatment known to cause major organ system toxicity during the past year.
  • Use of any drug that is a strong inducer/inhibitor of CYP3A4 within 4 weeks before baseline.

Sites / Locations

  • UCLA
  • The Ataxia-Telangiectasia Clinical Center, The Johns Hopkins Hospital
  • Cincinnati Children's Hospital Medical Center
  • UT Health
  • Royal Children's Hospital
  • Laboratoriumgeneeskunde
  • Klinik für Kinder- und Jugendmedizin Pädiatrische Allergologie, Pneumologie und Mukoviszidose, Universitätsklinikum Frankfurt
  • National Institute of Mental Health and Neurosciences
  • Amrita Institute of Medical Sciences and Research Centre
  • Jaslok Hospital and Research Centre
  • PD Hinduja National Hospital and Medical Research
  • Vijaya Health Centre, Department of Neurology
  • Nizam's Institute of Medical Sciences
  • All India Institute of Medical Sciences
  • Sheba Medical Center
  • U.O. Neurologia e Psichiatria dell'Infanzia e dell' Adolescenza. ASST Spedali Civili, Piazzale Spedali Civili, 1
  • Dipartimento di Pediatria e Neuropsichiatria Infantile, Università Sapienza di Roma, Azienda Policlinico Universitario Umberto I
  • Norwegian National Unit for Newborn Screening, Division of Pediatric and Adolescent Medicine, Oslo University Hospital
  • Department of Clinical Immunology The Children's Memorial Health Institute
  • Hospital Universitario La Paz.
  • El Razi Hospital
  • Nottingham University Hospitals NHS Trust - Queen's Medical Centre

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

EDS-EP dose range of ~5-10 mg DSP/infusion

EDS-EP dose range of ~14-22 mg DSP/infusion

Placebo EDS infusion

Arm Description

Drug: EDS-EP dose range of ~5-10 mg DSP/infusion EDS-EP dose range of ~5-10 mg DSP/infusion: A DSP loading quantity of 50.0 mg will be added to the EDS process, by using 2.0 mL of the 25 mg/mL DSP solution to deliver an EDS dose range of ~5-10 mg. DSP is diluted with 11 mL sterile water for injection in the same syringe, for a total of 13.0 mL. Other Names: EryDex System end product

Drug: DSP/infusion EDS-EP dose range of ~14-22 mg DSP/infusion DSP/infusion EDS-EP dose range of ~14-22 mg DSP/infusion: A DSP loading quantity of 125 mg will be added to the EDS process, by using 5.0 mL of the 25 mg/mL DSP solution to deliver an EDS dose range of 14-22 mg. DSP is diluted with 11 mL sterile water for injection in the same syringe, for a total of 16 mL. Other Names: EryDex System end product

Patients will be treated with autologous erythrocytes prepared with the EDS process using a placebo solution (5 mL of 0.372% NaCl solution) instead of experimental drug (DSP). Placebo is diluted with 11 mL sterile water for injection in the same syringe, for a total of 16 mL.

Outcomes

Primary Outcome Measures

Modified International Cooperative Ataxia Rating Scale (mICARS)
Change from baseline analyzed using a Mixed Model Repeated Measures (MMRM) approach

Secondary Outcome Measures

Clinical Global Impression of Change (CGI-C) key secondary outcome measure
Change from baseline analyzed using ANCOVA
Clinical Global Impression of Severity (CGI-S) of neurological symptoms of AT
Change from baseline
Vineland Adaptive Behavior Scales (VABS)
Change from baseline

Full Information

First Posted
May 2, 2016
Last Updated
August 6, 2021
Sponsor
Erydel
search

1. Study Identification

Unique Protocol Identification Number
NCT02770807
Brief Title
EDS in Ataxia Telangiectasia Patients
Acronym
ATTeST
Official Title
Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients With Ataxia Telangiectasia
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
March 2, 2017 (Actual)
Primary Completion Date
January 15, 2021 (Actual)
Study Completion Date
June 24, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Erydel

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is an international, multi-center, one-year, randomized, prospective, double-blind, placebo-controlled, phase III study, designed to assess the effect of two non-overlapping dose ranges of EDS EP, administered by IV infusion once per month, on neurological symptoms of patients with Ataxia Telangiectasia.
Detailed Description
All patients who complete the assessments as designed over the initial 6 months of the trial will be eligible to continue in an additional 6-month, double-blind, placebo-controlled extension designed to collect information on the long-term safety and efficacy of the trial treatments. Upon completion of all screening assessments for eligibility patients meeting all selection criteria at baseline will be randomized in a 1:1:1 fashion to one of the two EDS-EP dose levels or placebo. A minimization procedure will be employed to ensure that the proportions of male and female, and younger (6 to <10 years) and older (≥10 years), patients are comparable across the three treatment groups. Every attempt will be made to ensure the same balance is achieved across different regions. A minimum of 180 patients will be enrolled, hence, each group will consist of 60 patients randomly assigned to receive one of the two doses of EDS-EP or placebo, as follows: Group 1: EDS-EP dose range of ~5-10 mg D SP/infusion, Group 2: EDS-EP dose range of ~14-22 mg D SP/infusion, Group 3: Placebo EDS infusion. The initial 6-month treatment period will be considered complete when the endpoint assessment (at Visit 9/Month 6 or at early discontinuation) has been performed for all patients. Patients who are not experiencing severe side-effects, or have deteriorated significantly while on the treatment and provide informed consent will be eligible to continue treatment for an additional 6 months in a double-blind, placebo-controlled extension treatment period. Patients meeting all entry criteria will be treated as follows: Patients originally randomized to EDS-EP treatment groups (Group 1 or Group 2) will continue on the same treatment; Patients originally randomized to the Placebo group (Group 3) will be re-randomized in equal proportions (1:1) to receive either the EDS-EP ~5-10 mg DSP/infusion or ~14-22 mg DSP/infusion, as follows: Following 6 months of treatment, one third of the originally randomized placebo patients will be re-randomized to treatment with EDS-EP, as described above; After 9 months of treatment, one third of the originally randomized placebo patients will be re-randomized to treatment with EDS-EP, as described above; At 12 months, all remaining placebo patients who continue open-label treatment will receive treatment with EDS-EP, as described above. The ICARS will be administered by a site rater and scoring verified by a central remote qualified rater, based on a video recording of the assessment at the site. The scores provided by the central remote raters will be used for the primary analysis of the 'Modified' ICARS (primary efficacy endpoint). The site ICARS rater will not be involved in the rating of the CGI- S and CGI-C, VABS, or QoL scale. The CGI rater will not have access to the ICARS ratings, but may refer to other scales in scoring the CGI. All patients who complete 12 months of treatment in the trial, complete the study assessments, and provide informed consent will be eligible to continue treatment with EDS-EP in an open-label, extension study (IEDAT-03-2016). Retrieved drop-outs (RDO), i.e. patients who discontinued treatment prematurely but completed the final (Visit 15/Month 12) efficacy assessments will also be eligible to enter the open-label extension study. Patients will continue on the dose of EDS-EP they were receiving at the end of Study IEDAT-02, or if on placebo, the patient will be randomly switched (1:1) to one of the two doses of EDS-EP.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nervous System Disease, Genetic Syndrome
Keywords
Ataxia Teleangiectasia, AT, EryDex system, Dexamethasone, Dexamethasone sodium phosphate

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Masking Description
Double Blind ( Subject, Caregiver, Investigator)
Allocation
Randomized
Enrollment
175 (Actual)

8. Arms, Groups, and Interventions

Arm Title
EDS-EP dose range of ~5-10 mg DSP/infusion
Arm Type
Experimental
Arm Description
Drug: EDS-EP dose range of ~5-10 mg DSP/infusion EDS-EP dose range of ~5-10 mg DSP/infusion: A DSP loading quantity of 50.0 mg will be added to the EDS process, by using 2.0 mL of the 25 mg/mL DSP solution to deliver an EDS dose range of ~5-10 mg. DSP is diluted with 11 mL sterile water for injection in the same syringe, for a total of 13.0 mL. Other Names: EryDex System end product
Arm Title
EDS-EP dose range of ~14-22 mg DSP/infusion
Arm Type
Experimental
Arm Description
Drug: DSP/infusion EDS-EP dose range of ~14-22 mg DSP/infusion DSP/infusion EDS-EP dose range of ~14-22 mg DSP/infusion: A DSP loading quantity of 125 mg will be added to the EDS process, by using 5.0 mL of the 25 mg/mL DSP solution to deliver an EDS dose range of 14-22 mg. DSP is diluted with 11 mL sterile water for injection in the same syringe, for a total of 16 mL. Other Names: EryDex System end product
Arm Title
Placebo EDS infusion
Arm Type
Placebo Comparator
Arm Description
Patients will be treated with autologous erythrocytes prepared with the EDS process using a placebo solution (5 mL of 0.372% NaCl solution) instead of experimental drug (DSP). Placebo is diluted with 11 mL sterile water for injection in the same syringe, for a total of 16 mL.
Intervention Type
Drug
Intervention Name(s)
EDS-EP dose range of ~5-10 mg DSP/infusion
Other Intervention Name(s)
EryDex System end product
Intervention Description
infusion
Intervention Type
Drug
Intervention Name(s)
EDS-EP dose range of ~14-22 mg DSP/infusion
Other Intervention Name(s)
EryDex System end product
Intervention Description
infusion
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
infusion
Primary Outcome Measure Information:
Title
Modified International Cooperative Ataxia Rating Scale (mICARS)
Description
Change from baseline analyzed using a Mixed Model Repeated Measures (MMRM) approach
Time Frame
3 months, 6 months, 9 months, 12 months
Secondary Outcome Measure Information:
Title
Clinical Global Impression of Change (CGI-C) key secondary outcome measure
Description
Change from baseline analyzed using ANCOVA
Time Frame
3 months, 6 months, 9 months, 12 months
Title
Clinical Global Impression of Severity (CGI-S) of neurological symptoms of AT
Description
Change from baseline
Time Frame
3 months, 6 months, 9 months, 12 months
Title
Vineland Adaptive Behavior Scales (VABS)
Description
Change from baseline
Time Frame
3 months, 6 months, 9 months, 12 months
Other Pre-specified Outcome Measures:
Title
Quality of Life (QoL) EQ-5D-5L scale
Description
Change from baseline
Time Frame
3 months, 6 months, 9 months, 12 months
Title
Number of Treatment-Emergent Adverse Events (TEAEs)
Description
Change from baseline
Time Frame
3 months, 6 months, 9 months, 12 months
Title
Vital Signs
Description
Change from baseline - results will be summarized descriptively, with abnormal and clinically notable values/findings being identified
Time Frame
3 months, 6 months, 9 months, 12 months
Title
Laboratory parameters
Description
Change from baseline - results will be summarized descriptively, with abnormal and clinically notable values/findings being identified
Time Frame
3 months, 6 months, 9 months, 12 months
Title
ECGs
Description
Change from baseline - results will be summarized descriptively, with abnormal and clinically notable values/findings being identified
Time Frame
3 months, 6 months, 9 months, 12 months
Title
Number of participants with abnormal physical findings assessed per system
Description
Change from baseline - questionnaire will be used to assess as normal or abnormal physical findings per system
Time Frame
3 months, 6 months, 9 months, 12 months
Title
Number of participants with abnormal neurological findings assessed per cranial, motor, sensory, coordination nerves
Description
Change from baseline - questionnaire will be used to assess as normal or abnormal physical findings per nerve
Time Frame
3 months, 6 months, 9 months, 12 months
Title
Columbia-Suicide Severity Rating Scale (C- SSR S) Columbia-Suicide Severity Rating Scale (C- SSR S)
Description
Change from baseline analyzed using ANCOVA
Time Frame
3 months, 6 months, 9 months, 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Main Inclusion Criteria: Patient meets clinical criteria for diagnosis of AT. The neurological signs of AT (incoordination of the head and eyes in lateral gaze deflection, gait ataxia associated with an inappropriately narrow base) must be documented. Patient is in autonomous gait or is helped by periodic use of a support. Patient will be investigated for the proven genetic diagnosis of AT (prior documentation or by central laboratory test report). Patient is at least 6 years of age, of either sex Body weight > 15 kg. The patient and his/her parent/caregiver (if below the age of consent), or a legal representative, has provided written informed consent to participate. If consent is provided solely by the caregiver in accordance with local regulations, the patient must provide assent to participate in the study. Main Exclusion Criteria: General Females that are pregnant, or are breast-feeding (for EU countries only); of childbearing potential, pregnant, or are breast-feeding (for US and Rest of World countries). Females of childbearing potential using adequate birth control, as determined by their Health Care Provider, will be eligible. A disability that may prevent the patient from completing all study requirements. Current participation in another clinical study. Medical History and Current Status CD4+ lymphocytes count <400/mm3 (for patients 6 years of age) or <150/mm3 (for patients >6 years). In presence of oral infections, like oral candidiasis, documented at the screening or recurrent as per medical history documentation, the limit increases to <200/mm3 (for patients > 6 years). Loss/removal of 250 mL or more of blood within the past 4 weeks prior to screening. Current neoplastic disease or previous neoplastic disease not in remission for at least 2 years. History of severe impairment of the immunological system. Severe or unstable pulmonary disease. Uncontrolled diabetes. Patients with diabetes that has been stabilized (i.e. no hypoglycemic or hyperglycemic episodes in the past 3 months) will be eligible. Any other severe, unstable, or serious disease or condition that in the Investigator's opinion would put the patient at risk for imminent life-threatening morbidity, need for hospitalization, or mortality. Any clinically significant abnormality on standard laboratory examinations (hematology, biochemistry, urinalysis) at screening that remains abnormal on repeat testing. Eligibility of patients with abnormal laboratory test values will be determined by the Investigator in consultation with the Medical Monitor. Confirmed hemoglobinopathies, e.g. hemoglobin C disease, sickle cell anemia, or thalassemia. Moderate or severe renal and/or hepatic impairment. Prior/Concomitant Medication Any previous oral or parenteral steroid use within 4 weeks before Baseline. Treatment with inhaled or intranasal steroids for asthma or allergies, as well as use of topical steroids will be permitted Chronic condition or prior allergic reaction representing a contraindication to the use of dexamethasone or other steroid drugs. Has participated in any other trial with an investigational drug and received a dose within 30 days or 10 half-lives (whichever is greater) from the start of the 30-day Screening Period. Has participated in a previous trial with EDS. Requires any concomitant medication prohibited by the protocol. Has taken a drug or treatment known to cause major organ system toxicity during the past year. Use of any drug that is a strong inducer/inhibitor of CYP3A4 within 4 weeks before baseline.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guenter R. Janhofer, MD, PhD
Organizational Affiliation
EryDel S.p.A
Official's Role
Study Director
Facility Information:
Facility Name
UCLA
City
Los Angeles
State/Province
California
ZIP/Postal Code
900951694
Country
United States
Facility Name
The Ataxia-Telangiectasia Clinical Center, The Johns Hopkins Hospital
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287-3923
Country
United States
Facility Name
Cincinnati Children's Hospital Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229-3039
Country
United States
Facility Name
UT Health
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Royal Children's Hospital
City
Melbourne
State/Province
Victoria
Country
Australia
Facility Name
Laboratoriumgeneeskunde
City
Leuven
Country
Belgium
Facility Name
Klinik für Kinder- und Jugendmedizin Pädiatrische Allergologie, Pneumologie und Mukoviszidose, Universitätsklinikum Frankfurt
City
Frankfurt
State/Province
Hessen
ZIP/Postal Code
60590
Country
Germany
Facility Name
National Institute of Mental Health and Neurosciences
City
Bangalore
State/Province
Karnataka
ZIP/Postal Code
560 029
Country
India
Facility Name
Amrita Institute of Medical Sciences and Research Centre
City
Kochi
State/Province
Kerala
ZIP/Postal Code
682041
Country
India
Facility Name
Jaslok Hospital and Research Centre
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400026
Country
India
Facility Name
PD Hinduja National Hospital and Medical Research
City
Mahim
State/Province
Mumbai
ZIP/Postal Code
400016
Country
India
Facility Name
Vijaya Health Centre, Department of Neurology
City
Chennai
State/Province
Tamil Nadu
ZIP/Postal Code
600026
Country
India
Facility Name
Nizam's Institute of Medical Sciences
City
Hyderabad
State/Province
Telangana
ZIP/Postal Code
500082
Country
India
Facility Name
All India Institute of Medical Sciences
City
New Delhi
ZIP/Postal Code
110029
Country
India
Facility Name
Sheba Medical Center
City
Tel HaShomer
Country
Israel
Facility Name
U.O. Neurologia e Psichiatria dell'Infanzia e dell' Adolescenza. ASST Spedali Civili, Piazzale Spedali Civili, 1
City
Brescia
ZIP/Postal Code
25123
Country
Italy
Facility Name
Dipartimento di Pediatria e Neuropsichiatria Infantile, Università Sapienza di Roma, Azienda Policlinico Universitario Umberto I
City
Rome
ZIP/Postal Code
00185
Country
Italy
Facility Name
Norwegian National Unit for Newborn Screening, Division of Pediatric and Adolescent Medicine, Oslo University Hospital
City
Oslo
Country
Norway
Facility Name
Department of Clinical Immunology The Children's Memorial Health Institute
City
Warsaw
ZIP/Postal Code
04-730
Country
Poland
Facility Name
Hospital Universitario La Paz.
City
Madrid
Country
Spain
Facility Name
El Razi Hospital
City
Manouba
ZIP/Postal Code
2010
Country
Tunisia
Facility Name
Nottingham University Hospitals NHS Trust - Queen's Medical Centre
City
Nottingham
State/Province
Nottinghamshire
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

EDS in Ataxia Telangiectasia Patients

We'll reach out to this number within 24 hrs